gadoxetic acid enhanced liver MRI — Competitive Intelligence Brief

gadoxetic acid enhanced liver MRI (gadoxetic acid enhanced liver MRI) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gadolinium-based contrast agent. Area: Diagnostic Imaging.

marketed Gadolinium-based contrast agent Organic anion transporter 1B1/1B3 (OATP1B1/1B3) Diagnostic Imaging Small molecule

Target snapshot

gadoxetic acid enhanced liver MRI (gadoxetic acid enhanced liver MRI) — Seoul National University Hospital. Gadoxetic acid is a gadolinium-based contrast agent that accumulates in hepatocytes to enhance MRI visualization of liver tissue and detect lesions.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
gadoxetic acid enhanced liver MRI TARGET	gadoxetic acid enhanced liver MRI	Seoul National University Hospital	marketed	Gadolinium-based contrast agent	Organic anion transporter 1B1/1B3 (OATP1B1/1B3)
Gadavist	GADOBUTROL	Bayer	marketed	Gadolinium-based Contrast Agent [EPC]		2011-01-01
Gadovist®/Gadavist®	Gadovist®/Gadavist®	Guerbet	marketed	Gadolinium-based contrast agent	Water proton relaxation (T1 relaxation enhancement)
Dotarem®-enhanced MRI	Dotarem®-enhanced MRI	Guerbet	marketed	Gadolinium-based contrast agent	Water proton relaxation (T1 relaxation time)
Gadoterate (Dotarem/Clariscan)	Gadoterate (Dotarem/Clariscan)	Bayer	marketed	Gadolinium-based contrast agent	Water protons (via paramagnetic gadolinium ion)
DOTAREM	DOTAREM	Guerbet	marketed	Gadolinium-based contrast agent	Water proton relaxation (T1 and T2 relaxation times)
MultiHance 0.05 mmol/kg	MultiHance 0.05 mmol/kg	Bracco Diagnostics, Inc	marketed	Gadolinium-based contrast agent	Water proton relaxation (T1 relaxation enhancement)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Gadolinium-based contrast agent class)

1. Guerbet · 4 drugs in this class
2. Bayer · 4 drugs in this class
3. Paracelsus Medical University · 2 drugs in this class
4. GE Healthcare · 1 drug in this class
5. Bracco Diagnostics, Inc · 1 drug in this class
6. Seoul National University Hospital · 1 drug in this class
7. Shanghai Shengdi Pharmaceutical Co., Ltd · 1 drug in this class
8. The Central Hospital of Lishui City · 1 drug in this class